证券代码：688488 证券简称：艾迪药业 公告编号：2025-037 江苏艾迪药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 7 月 14 日 （二） 股东会召开的地点：南京市玄武区玄武大道 699-18 号百家汇社区 20 栋 5 楼 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 133 | | --- | --- | | 普通股股东人数 | 133 | | 2、出席会议的股东所持有的表决权数量 | 213,859,404 | | 普通股股东所持有表决权数量 | 213,859,404 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.8241 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 50.82 ...

股及股份变更查询证明》及《股东股份变更明细清单》，在本次激励计划自查期 间，有 9 名核查对象存在公司股票交易行为，其余人员在自查期间内均不存在买 卖公司股票的行为。 经上述核查对象书面承诺，其在自查期间内买卖股票的行为系基于对二级市 场交易情况自行判断而进行的操作，与公司本次激励计划的内幕信息无关。在本 "核查对象"）。 划首次公开披露前六个月内买卖公司股票情况进行了查询，并由中国证券登记结 算有限公司上海分公司出具了书面的查询证明。 二、核查对象买卖公司股票情况说明 法律法规和规范性文件，公司通过中国证券登记结算有限责任公司上海分公司对 本次激励计划的内幕信息知情人和激励对象在本次激励计划草案公开披露前 6 个月内（即 2024 年 12 月 28 日至 2025 年 6 月 27 日，以下简称"自查期间"）买 卖公司股票的情况进行了自查，具体情况如下： 一、核查的范围与程序 《上市公司 信息披露管理办法》及公司内部制度的有关规定，公司对 2025 年股票期权激励 计划（以下简称"本次激励计划"）采取了充分必要的保密措施，对本次激励计 划的内幕信息知情人进行了登记。根据《管理办法》《上海证券交易所科创板股 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2025-037 江苏艾迪药业股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 7 月 14 日 （二） 股东会召开的地点：南京市玄武区玄武大道 699-18 号百家汇社区 20 栋 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 普通股股东人数 133 普通股股东所持有表决权数量 213,859,404 例（%） 普通股股东所持有表决权数量占公司表决权数量的比例（%） 50.8241 （四） 表决方式是否符合《公司法》及公司章程的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长傅和亮先生主持，采用现场投票与网 络投票相结合的方式召开。本次会议的召集、召开及表决方式符合《中华人民共 和国公司法》《上海证券交易所科创板股票上市规则》及《公司章程》的相关规 定。 （五） 公司董事、监事和董事 ...

及激励对象买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 了第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于公司 ＜2025 年股票期权激励计划（草案）＞及其摘要的议案》等相关议案，并于 2025 年 6 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上市公司 信息披露管理办法》及公司内部制度的有关规定，公司对 2025 年股票期权激励 计划（以下简称"本次激励计划"）采取了充分必要的保密措施，对本次激励计 划的内幕信息知情人进行了登记。根据《管理办法》《上海证券交易所科创板股 票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励信息披露》等 法律法规和规范性文件，公司通过中国证券登记结算有限责任公司上海分公司对 本次激励计划的内幕信息知情人和激励对象在本次激励计划草案公开披露前 6 个月 ...

Core Insights - The report emphasizes the flourishing approval of new drugs and highlights the importance of focusing on technological tracks and opportunities within the industry chain [1][5] - It suggests a dual growth strategy combining internal and external growth, particularly in the context of the imminent patent cliff for IO1.0 and the increasing recognition of Chinese innovative pharmaceutical companies globally [5] Industry Overview - The report notes a significant recovery in domestic healthcare policies, including the integration of commercial insurance into the medical insurance system and the inclusion of high-priced innovative drugs in the Class B medical insurance catalog [5] - The overall revenue growth rate for chemical pharmaceutical companies in 2024 is projected at 4.10%, a substantial increase from 0.24% in 2023, while the net profit growth rate is expected to be 51.66% [12][15] Investment Opportunities - Short-term focus is recommended on certain tracks with high certainty, such as IO+ADC, while long-term investments should target new technologies with significant potential, including small nucleic acids and CAR-T [5] - The report categorizes various technological tracks for investment, including combinations of PD-1 with other mechanisms and innovative solutions for unmet clinical needs [5] Company Valuations - The report provides a comparative valuation of unprofitable innovative pharmaceutical companies, highlighting their market capitalizations and projected revenues for 2024 to 2027 [6] - It also presents a comparative valuation of profitable innovative pharmaceutical companies, detailing their market capitalizations and projected net profits for the same period [8] Performance Review - The report reviews the performance of pharmaceutical companies in 2024 and Q1 2025, noting that while the overall industry faced temporary pressure, gross profit margins have steadily improved [12][15] - It highlights that many small and mid-cap innovative pharmaceutical companies have turned profitable in Q1 2025, indicating a positive trend in the sector [18]

Group 1 - The pharmaceutical industry in Jiangsu province is increasingly adopting a "go global" strategy, with banks like China Construction Bank (CCB) providing innovative financial services to support this initiative [1] - CCB Jiangsu branch is enhancing financial products and services to support the entire lifecycle of pharmaceutical companies, facilitating efficient cross-border transactions [1] - Eddy Pharmaceutical, a listed company focused on HIV drug development, is expanding into the African market while improving its domestic procurement processes through digital upgrades [2][3] Group 2 - CCB Yangzhou branch has formed a dedicated team to assist Eddy Pharmaceutical in optimizing its payment processes, leading to significant improvements in fund turnover efficiency [3] - In March 2025, Eddy Pharmaceutical successfully processed a payment of 10 million yuan through CCB's supply chain products, ensuring stable raw material supply and enhancing its reputation in the supply chain [3] - CCB Jiangsu branch has provided over 50 million yuan in credit support to Eddy Pharmaceutical, facilitating its international expansion efforts [3] Group 3 - Yuyue Group is actively expanding its international market presence, with CCB Zhenjiang branch providing substantial financial support, including a 3 billion yuan loan for acquisitions [4] - As of March 2025, CCB Zhenjiang branch has granted a total credit of 2.64 billion yuan to Yuyue Group, enabling the company to overcome barriers in overseas markets [4] - Yuyue Group's subsidiary, Juyue Medical, has secured a credit line of 60 million yuan from CCB Zhenjiang branch, further supporting its operational needs [4] Group 4 - CCB Lianyungang branch has been closely monitoring a well-known pharmaceutical group, assisting in resolving a cross-border RMB transaction that had been pending for nearly a year due to compliance issues [6][7] - The bank conducted a rapid compliance review and successfully processed the transaction within 48 hours, thereby maintaining the company's international business reputation [6][7] - This collaboration exemplifies CCB's commitment to supporting pharmaceutical companies in their international endeavors through effective cross-border RMB services [7]

Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]

Core Viewpoint - The company has approved the initial list of incentive recipients for the 2025 stock option incentive plan, ensuring compliance with relevant regulations and internal governance [1][2][3] Disclosure Situation - The company publicly disclosed the names and positions of the proposed incentive recipients internally from June 27, 2025, to July 7, 2025, for a minimum of 10 days, allowing employees to provide feedback [1] Review Method - The supervisory board verified the proposed recipients' identities, employment contracts, and positions within the company and its subsidiaries [2] Supervisory Board Review Opinion - The supervisory board confirmed that all proposed recipients meet the qualifications set forth by relevant laws and regulations, including not being disqualified by the securities exchange or regulatory authorities in the past 12 months [2][3]

证券代码：688488 证券简称：艾迪药业 公告编号：2025-035 江苏艾迪药业股份有限公司 监事会关于 2025 年股票期权激励计划 公司于 2025 年 6 月 27 日至 2025 年 7 月 7 日，通过办公 OA 系统在公司内 部对本次拟激励对象的姓名和职务进行了公示，公示时间不少于 10 天，公司员 工可在公示期限内向监事会提出反馈意见。 至公示期满，公司监事会未收到任何组织或个人对本次拟激励对象的异议。 二、审核方式 公司监事会对拟激励对象的核查方式：公司监事会核查了本激励计划拟首次 授予激励对象的名单、身份证件、拟首次授予激励对象与公司（含子公司）签订 的劳动合同/劳务合同、首次授予激励对象在公司（含子公司）担任的职务及其 任职文件等。 三、监事会核查意见 监事会根据《管理办法》的规定，对本激励计划首次授予激励对象名单进行 了核查，并发表核查意见如下： 首次授予激励对象名单的审核意见及公示情况说明 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 ...

江苏艾迪药业股份有限公司 董事会薪酬与考核委员会 关于 2025 年股票期权激励计划 首次授予激励对象名单的审核意见及公示情况说明 证券代码：688488 证券简称：艾迪药业 公告编号：2025-036 2、激励对象不存在《管理办法》规定的不得成为激励对象的情形： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开 第三届董事会第四次会议、第三届监事会第四次会议，审议通过了《关于公司＜ 2025 年股票期权激励计划（草案）＞及其摘要的议案》等相关议案。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券 交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激 励信息披露》的相关规定，对公司《2025 年股票期权激励计划（草案）》（以下 简称"《激励计划（草案）》"、"本激励计划"）中拟首次授予激励对象的姓名和职 务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情况对本激励 计划拟首次授予激励对象 ...